





## MELANOMA RESEARCH AND THERAPY IN NEW ZEALAND: RAISING THE BAR THROUGH COLLABORATIVE ACTION

## **QRW Programme**

## Melanoma Research and Therapy in New Zealand: Raising the Bar through Collaborative Action

Saturday 9 September 2017 Rydges Hotel, Queenstown, New Zealand

Time	Details	Location
	Session 1	
8.00am - 8.30am	Opening	Clancys Room
	Professor Peter Shepherd	
	Queenstown Research Week	
	Challenge to participants	
	Paul O'Neil	
	Melanoma New Zealand	
	Scene setting and meeting aim	
	Dr Rosalie Stephens	
	Melanoma New Zealand	
	Professor Mike Eccles sponsored by Bio-Strategy	
	Melanoma Network of New Zealand (MelNet)	
8.30am - 9.15am	Professor David Whiteman (M1) sponsored by MelNet	Clancys Room
	and Thermo Fisher Scientific	
	Department of Population Health, QIMR Berghofer	
	Medical Research Institute, Brisbane, Australia	
	Melanoma epidemiology and risk assessment	
9.15am - 10.00am	Professor Mel Ziman (M2) sponsored by Maurice and	Clancys Room
	Phyllis Paykel Trust and Bio-Rad Laboratories Pty Ltd	
	School of Medical and Health Sciences, Edith Cowan	
	University, Perth, Australia	
	Blood based biomarkers for diagnosis, prognosis and	
	monitoring of patients with melanoma	
10.00am - 10.30am	Morning tea	Level 5 Foyer
	Session 2	
10.30am - 11.15am	Professor Mark Shackleton (M3) sponsored by Merke	Clancys Room
	Sharp Dohme New Zealand and Thermo Fisher Scientific	
	Alfred Health and Monash University, Melbourne,	
	Australia	
	Melanoma heterogeneity – the elephant in the room	
11.15am - 12.00pm	Dr Michelle Wilson (M4)	Clancys Room
	Auckland City Hospital, Auckland, New Zealand	
	Paul O'Neil (M4), sponsored by Merke Sharp Dohme New	

Zealand	
Melanoma New Zealand	
Understanding and facilitating clinical research in	
melanoma	

12.00pm - 1.00pm	Lunch and concurrent poster session	Level 5 Foyer
12.00pm – 1.00pm	Poster Session	Clancys Room

	Session 3	
1.00pm - 3.00pm	Dr Mary Jane Sneyd (M5) sponsored by MelNet	Clancys Room
	HACEU, University of Otago, Dunedin, New Zealand	
	An online melanoma risk prediction tool specifically for	
	New Zealanders	
	Professor Mike Eccles (M6) sponsored by Bio-Strategy	
	Department of Pathology, University of Otago, Dunedin,	
1	New Zealand	
	Can research involving NZ melanoma patient	
	participation and extensive networking by researchers	
	help reduce the melanoma burden in NZ?	
	Professor Rod Dunbar (M7) sponsored by Thermo Fisher	
	Scientific	
	Maurice Wilkins Centre & School of Biological Sciences,	
	University of Auckland, Auckland, New Zealand	
	Making immune therapy work for more melanoma	
	patients	
	Professor Cristin Print (M8) sponsored by Bio-Strategy	
	Department of Molecular Medicine and Pathology,	
	University of Auckland, Auckland, New Zealand	
	The promise and challenge of melanoma genomics	
	Professor Bruce Baguley (M9)	
	Auckland Cancer Society Research Centre, University of	
	Auckland, Auckland, New Zealand	
	Growing melanoma cells from surgical samples: what	
	have we learnt?	
	Professor Peter Shepherd (M10) sponsored by Bio-Rad	
	Laboratories Pty Ltd	
	Auckland Cancer Society Research Centre, University of	
	Auckland, Auckland, New Zealand	
	Lessons for melanoma therapy gained from studies in	
	the NZM melanoma cell line panel	
	Dr Jacqui Gardner (M11)	
	Department of Pathology, Canterbury District Health	
	Board, Christchurch, New Zealand	
	Working towards a molecular classification of	
	melanoma	
3.00pm - 3.30pm	Afternoon tea	Level 5 Foyer

	Session 4	
3.30pm - 4.15pm	Mr Richard Martin (M12)	Clancys Room
	Melanoma Unit and Waitemata District Health Board,	
	Auckland, New Zealand	
	What role does the surgeon have in contemporary	
	melanoma management and research?	
	Dr Rosalie Stephens (M13)	
	Auckland City Hospital, Auckland, New Zealand	
	Strategies to improve access to melanoma clinical	
	research in New Zealand	
	Dr Sanjeev Deva (M14)	
	Auckland City Hospital, Auckland, New Zealand	
	Establishment of an early phase clinical trials unit	
4.15pm - 5.00pm		Clancys Room
	Dr Cristin Print sponsored by Bio-Strategy	
5.00pm - 6.00pm	Social hour	Reds Bar

## Poster Session Summary 12pm – 1pm Clancys Room

No.	Title	Presenter	Institutions
M15	Genomic variations of the mevalonate pathway and roles of bisphosphonate in melanoma	Khanh Tran	Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand
M16	Development of single-cell methodologies to interrogate DNA methylation patterns at a whole genome scale	Dr. Aniruddha Chatterjee	University of Otago, Dunedin, New Zealand
M17	Stratification of melanoma patients according to PD-L1 expression, CpG methylation and presence of tumour-infiltrating lymphocytes	Dr Euan Rodger	University of Otago, Dunedin, New Zealand
M18	Epigenetic drivers of melanoma metastasis identified by genome-wide reduced-representation bisulphite sequencing (RRBS) analysis	Professor Mike Eccles	University of Otago, Dunedin, New Zealand
M19	Characterizing the therapeutic potential of crizotinib in cutaneous malignant melanoma	Elisha Hayden	Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand